Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)

Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal hematologic disorders characterized by morphologic dysplasia, ineffective hematopoiesis, and cytopenia. In the past year, the classification of MDS has been updated in the 5th edition of the World Health Organization (WHO) Classifica...

Full description

Bibliographic Details
Main Authors:	Josephine Lucero, Salman Al-Harbi, Karen W. L. Yee
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Current Oncology
Subjects:	myelodysplastic neoplasm prognostic scoring system lenalidomide luspatercept antithymocyte globulin hypomethylating agent
Online Access:	https://www.mdpi.com/1718-7729/30/7/459

Similar Items

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Myelodysplastic syndromes: therapeutic problems and decisions (review)
by: S. V. Semochkin, et al.
Published: (2014-07-01)

Targeting the Microenvironment in MDS: The Final Frontier
by: Patric Teodorescu, et al.
Published: (2020-07-01)

Current Therapy of the Patients with MDS: Walking towards Personalized Therapy
by: Maria Luisa Palacios-Berraquero, et al.
Published: (2021-05-01)

Molecular Drivers of Myelodysplastic Neoplasms (MDS)—Classification and Prognostic Relevance
by: Fieke W. Hoff, et al.
Published: (2023-02-01)

Myelodysplastic syndromes: Where do we stand?
by: Nitin Sood, et al.
Published: (2016-01-01)

Myelodysplastic syndrome from theoretical review to clinical application view
by: Amrallah A. Mohammad
Published: (2018-12-01)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
by: Esther Natalie Oliva, et al.
Published: (2021-12-01)

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure
by: Abigail Belasen, et al.
Published: (2020-07-01)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
by: Marion Divoux, et al.
Published: (2020-09-01)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
by: Hussein Awada, et al.
Published: (2023-04-01)

New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
by: E. V. Morozova, et al.
Published: (2022-11-01)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
by: Eleftheria Hatzimichael, et al.
Published: (2022-10-01)

Acute kidney injury with extreme hyperuricemia after antithymocyte globulin treatment in a kidney transplant recipient with underlying aplastic anemia: a case report
by: Yohan Park, et al.
Published: (2020-07-01)

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
by: Paul Lee, et al.
Published: (2021-09-01)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
by: Claudia Bănescu, et al.
Published: (2023-03-01)

Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review
by: Lucía Prieto-Torres, et al.
Published: (2023-12-01)

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge
by: Francesco Pisani, et al.
Published: (2014-04-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial
by: Hui Liu, et al.
Published: (2023-07-01)

Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
by: Bruno Mendes, et al.
Published: (2022-08-01)

Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin
by: de-Medeiros C.R., et al.
Published: (2000-01-01)

Evolution of Immune Checkpoint Blockade–Induced Myocarditis Over 2 Years
by: Timothy G. Norwood, et al.
Published: (2020-02-01)

Epigenetic Silencing of <i>PTEN</i> and Epi-Transcriptional Silencing of <i>MDM2</i> Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents
by: Paul Lee, et al.
Published: (2022-05-01)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
by: Wang Eunice S, et al.
Published: (2012-11-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Agentes imunossupressores, talidomida e ácido valpróico nas síndromes mielodisplásicas Immunosuppressive agents, thalidomide and valproate acid in myelodysplastic syndromes
by: Elvira R. P. Velloso
Published: (2006-09-01)

Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis
by: Tomoya Maeda, et al.
Published: (2021-01-01)

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies
by: Nina Kim, et al.
Published: (2018-08-01)

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform
by: Paul Lee, et al.
Published: (2022-04-01)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
by: Guangjie Zhao, et al.
Published: (2021-09-01)

Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report
by: Konstantinos Loukidis, et al.
Published: (2024-01-01)

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications
by: G. R. Pourmand, et al.
Published: (2012-04-01)

Acquired severe aplastic anemia treated with antithymocyte globulin and cyclosporine: An experience of regional cancer center, Western India
by: Ankit B Patel, et al.
Published: (2015-01-01)

Role of antithymocyte globulin in reducing the incidence of complications after allogeneic hemopoietic cell transplantation
by: Yu R Zalyalov, et al.
Published: (2010-08-01)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
by: Fianchi Luana, et al.
Published: (2012-08-01)

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
by: Pierre Fenaux, et al.
Published: (2017-06-01)

The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting
by: Charalampos G. Pontikoglou, et al.
Published: (2023-01-01)

Diagnostic and prognostic value of ferroptosis-related genes in patients with Myelodysplastic neoplasms
by: Xiaomei Chen, et al.
Published: (2023-12-01)